| Budget Amount *help |
¥53,950,000 (Direct Cost: ¥41,500,000、Indirect Cost: ¥12,450,000)
Fiscal Year 2014: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2013: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
Fiscal Year 2012: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2011: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2010: ¥13,000,000 (Direct Cost: ¥10,000,000、Indirect Cost: ¥3,000,000)
|
|---|
| Outline of Final Research Achievements |
The tumor microenvironment includes hematopoietic cells, endothelial cells, and cancer-associated fibroblasts. Hematopoietic-myeloid cells promote cancer growth by stimulating angiogenesis (formation of new blood vessels). Plasmin inhibition (pharmacological and genetic) prevented T cell lymphoma growth and diminished matrix metalloproteinase-9 (MMP-9)-dependent CD11b+F4/80+ myeloid cell infiltration into lymphoma tissues. Inflammatory bowel disease (IBD) and here especially ulcerative colitis patients are endowed with a high of developing colorectal cancer. Plasmin regulated IBD progression in models of IBD by activating MMP-9 and enhancing myeloid cell influx. Plasminogen activation not only activated other proteases like MMP-9, but also mobilized marrow derived CD45+CD11b+VEGFR-1+ cells, which promoted neovascularization. In summary, we have established a critical role of the fibrinolytic system for regulating the cellular composition of the tumor microenvironment.
|
